Entries |
Document | Title | Date |
20080200566 | Dephosphorylation of HDAC7 By Myosin Phosphatase - The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase. | 08-21-2008 |
20080200567 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS - A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases. | 08-21-2008 |
20080200568 | Genes Associated With Type ll Diabetes Mellitus - Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat diet and made insulin deficient by streptozocin injection. | 08-21-2008 |
20080214681 | TASTE REDUCING COMPOSITIONS AND RELATED METHODS - A method includes contacting a surface in an oral cavity with a first composition capable of reducing a taste of a selected material, and orally administering a second composition separate from the first composition, the second composition including the selected material. The selected material can include a drug, and/or the second composition can further include a drug. In some embodiments, the first and second compositions are included in a kit. | 09-04-2008 |
20080214682 | METHODS OF TREATING PNEUMONIC PLAGUE - The present invention relates to methods of treating pneumonic plague. More specifically, the present invention relates to methods of using plasmin or Pla inhibitors to treat pneumonic plague. | 09-04-2008 |
20080221224 | UNIMOLECULAR TWEEZERS - Macromolecules may be specially designed so that upon adsorption at a substrate, the macromolecules experience intramolecular tension at their covalent bonds due to the physical interaction of the molecular segments of the macromolecules with the substrate. As a result of the induced tension, the macromolecules may be used in a number of applications including, but not limited to, environmental and surface sensors, chemical activators and catalysts, and molecular probes. | 09-11-2008 |
20080221225 | Genes associated with restenosis - The present invention identifies genes whose gene products are differentially expressed during restenosis, including de novo restenosis and in stent restenosis (ISR). Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to restenosis. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing restenosis. | 09-11-2008 |
20080234393 | COMPOUNDS AND METHODS FOR DETECTION OF CARCINOMAS AND THEIR PRECURSOR LESIONS - The present invention relates to compounds and methods for detection and treatment of carcinomas and their precursor lesions. The invention provides DNase nucleic acids and polypeptides useful for the detection and treatment of carcinomas and their precursor lesions. The invention is more specifically related to a method for detection of carcinomas and their precursor lesions comprising the detection of the level and/or the subcellular localization of one or more DNase molecules in biological samples. Furthermore the present invention provides methods for early diagnosis, prognosis and monitoring of the disease course of carcinomas and their precursor lesions as well as for the treatment of said lesions. | 09-25-2008 |
20080242742 | Animal models of pancreatic adenocarcinoma and uses therefor - The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a/Arf, Ink4a, Arf, p53, Smad4/Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents. | 10-02-2008 |
20080255252 | Infectious Aetiology of Prostatic Disease and Methods to Identify Causative Agents - The present invention relates to a method of diagnosing, or predicting risk of, prostate disease in a subject. More particularly, the invention relates to a method of diagnosing the presence of, or the predisposition to develop, prostate disease in a subject, the method comprising analysing a test sample from the subject for the presence of | 10-16-2008 |
20080255253 | ANIMAL MODEL FOR PROSTATIC STROMAL HYPERPLASIA - The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom). | 10-16-2008 |
20080262108 | Method - The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of the binding affinity of CEL to receptors for the prevention and treatment of atherosclerosis. | 10-23-2008 |
20080262109 | METHOD FOR PRODUCING LIQUID PREPARATIONS HAVING A SOLID BODY CONTENT - A method for producing a liquid preparation having a solid body content and the resulting liquid preparation. According to the method, the addition of at least a portion of the solid bodies takes place only (a) in the last stage of the method preceding the pouring of the liquid preparation into a packing unit or (b) during the pouring into a packing unit. | 10-23-2008 |
20080293830 | Method For Activating Efferent Sympathetic Nerves Innervating Adipose Tissues To Improve Obesity And Symptoms Associated Therewith - A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-γ2 function in the liver. | 11-27-2008 |
20090012186 | Mite Composition, Use Thereof, Method for Rearing the Phytoseiid Predatory Mite Amblyseius Sirskii, Rearing System for Rearing Said Phytoseiid Mite and Methods for Biological Pest Control on a Crop - The present invention relates to a novel mite composition comprising a population of the phytoseiid predatory mite species | 01-08-2009 |
20090018218 | METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS - Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β | 01-15-2009 |
20090306230 | High Throughput Testing for Presence of Microorganisms in a Biological Sample - Provided are methods and apparatus for high throughput testing of biological samples that may or may not comprise microorganisms. The methods include the use of a diagnostic multiplexing panel (DMP) specifically designed for the simultaneous identification of a plurality of potential microorganisms that may be present in the biological sample via a primer extension reaction directed a highly conserved nucleic acid sequences in the microorganisms under test. The biological sample is typically immobilised on a solid substrate at a first location before being transferred to a second location for analysis using the DMP. The methods and apparatus of the invention are particularly suited to diagnosis of the presence of infectious pathogens in the biological sample, for example for diagnosis of sexually transmitted infection. | 12-10-2009 |
20100076095 | METHOD AND APPARATUS FOR MITIGATING ACUTE REOXYGENATION INJURY DURING PERCUTANEOUS CORONARY INTERVENTION - A system and methods are described for improving the management of ischemic cardiac tissue during acute coronary syndromes. The system combines a catheter-based sub-system which allows for simultaneous balloon dilation of a coronary artery and infusion of a carefully controlled perfusate during percutaneous coronary intervention. The system allows for modulation of levels of oxygen at the time of percutaneous intervention. In addition, catheters and systems are provided for administration of fluids with modified oxygen content during an intervention that incorporate upstream flow control members to compartmentalize the perfusion of the target coronary artery and the remainder of the heart. | 03-25-2010 |
20100144903 | METHODS OF DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus. | 06-10-2010 |
20100210738 | PROGNOSTIC BIOMARKERS TO PREDICT OVERALL SURVIVAL AND METASTATIC DISEASE IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER - The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer. Likewise, in another example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANG, DICER1, EIF1, and MSH6. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of metastasis of TN breast cancer. | 08-19-2010 |
20100280134 | Markers for Bladder Cancer Detection - A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The gene may be TWIST1 or a panel of genes such as TWIST1, NID2 and RUNX3 may be screened. The epigenetic change may be methylation. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises at least one primer pair for determining the methylation status of each of NID2, TWIST1 and RUNX3. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises means for detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. The kit also contains means for processing a urine sample. | 11-04-2010 |
20100286290 | ENZYME ACTIVITY ASSAY USING ROLLING CIRCLE AMPLIFICATION - The present invention relates to an enzyme activity assay using rolling circle amplification for verifying that a sample contains the enzyme activity in question. Thus, the present invention pertains to a method for determining the presence or absence of one or more enzyme activities involved in circularising a non-circular oligonucleotide probe in a biological sample. Furthermore, the present invention concerns liquid compositions comprising one or more oligonucleotide probes. Within the scope of the present invention is also a composition comprising a liquid composition and a tissue sample, and solid support of one or more oligonucleotides of the present invention. Disclosed is also a microfluidic device with one or more compartments for performing rolling circle amplification events, and a method for correlating one or more rolling circle amplification events. Methods for testing the efficacy of a drug, for diagnosing or prognosing a disease, for treating a disease, or for treating prophylactically a disease is furthermore disclosed. | 11-11-2010 |
20100286291 | MULTIPLEX DETECTION OF HEPATITIS VIRUS VARIATIONS - Disclosed is a method for the detection of virus variations. Disclosed also is a method for the treatment of virus infection in a subject based on the detection of virus variations. Additionally, a kit is provided for the detection of virus variations. | 11-11-2010 |
20100292348 | DETECTION OF METHYLATED DNA AND DNA MUTATIONS - The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence. | 11-18-2010 |
20100324154 | ASSESSING SUSCEPTIBILITY TO VASCULAR DISORDERS - The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases. | 12-23-2010 |
20110086925 | Method and System to Detect, Diagnose, and Monitor the Progression of Alzheimer's Disease - Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease. | 04-14-2011 |
20110086926 | Disabling thymus gland as a new method for treatment of multiple sclerosis - This invention is related to the treatment of the Multiple Sclerosis (MS). | 04-14-2011 |
20110124744 | Magnetic Resonance-Based Viscometers and Methods - This invention relates generally to magnetic resonance (MR)-based methods and kits for measuring the viscosity of liquid samples. | 05-26-2011 |
20110136922 | ACTIVATION INDUCED DEAMINASE (AID) - The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide. | 06-09-2011 |
20110152385 | NUCLEIC ACIDS AND METHODS FOR DETECTING TURFGRASS PATHOGENIC FUNGI - The present invention relates to the use of at least one nucleic acid comprising or consisting of: (i) CATCGAT-GAAGAACGCWGCRAAHTGCGATAMGTARTGYGAATTGCAGRATTCAGTGARTCATCGAAWYTTTGAACG-CAYMTTGCRC (SEQ ID NO: 1), wherein: R represents A or G Y represents C or T M represents A or C W represents A or T H represents A or C or T (ii) a portion of SEQ ID NO: 1, provided said nucleic acid binds under stringent conditions to a nucleic acid comprising or consisting of the complementary sequence of SEQ ID NO: 1, or (iii) complementary sequences of (i) and (ii); for the detection of nucleic acids from one or more fungi in a sample. | 06-23-2011 |
20110184073 | ASSAY - This invention relates to a method of detecting or determining the presence of prostate cancer cells in a sample of body fluid from a subject comprising: (i) isolating cells from said sample to provide a cell sample; (ii) contacting said cell sample with a specific binding member capable of binding a prostate antigen; and/or (iii) contacting said cell sample with a specific binding member capable of binding a minichromosome maintenance (MCM) polypeptide(s); and (iv) determining the binding of said specific binding member(s) to the cell sample. | 07-28-2011 |
20110218253 | IMAGING-BASED IDENTIFICATION OF A NEUROLOGICAL DISEASE OR A NEUROLOGICAL DISORDER - System(s) and method(s) are provided to enable imaging-based identification, detection, evaluation, and mapping of white matter microstructure and hemispheric organization of white matter in a central nervous system (CNS) structure afflicted by a neurological disease or disorder. Various embodiments exploit a set of diffusion tensor metrics to define a classification sub-space and determine a multivariate classifier through training data related to at least two groups of subjects: a first group of subjects afflicted by the neurological disease or neurological disorder, and a second group of subjects typically developing. The set of diffusion tensor metrics can be selected based at least on clinical information related to the neurological disease or neurological disorder and anatomy of CNS structure. Inclusion of tensor skewness asymmetry in such set yields an increase in sensitivity, specificity, accuracy, reliability, and predictive ability of the biological discrimination of subjects with and without a neurological disease or neurological disorder. | 09-08-2011 |
20110224313 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 09-15-2011 |
20110230571 | DIAGNOSTIC AND THERAPEUTIC PROTOCOLS - The present invention relates to methods for determining co-receptor usage of an HIV in a subject including the steps of: culturing a viral preparation derived from the subject's plasma with one or more cell lines which express surface CD4 and CCR5, surface CD4 and CXCR4, or surface CD4, CCR5 and CXCR4, wherein an anticoagulant is added to the viral preparation or to the culture; and screening for infection, wherein the presence or absence of infected cells is indicative of the co-receptors used by the HIV. | 09-22-2011 |
20110237688 | METHODS AND COMPOSITIONS RELATED TO ACETYLOCHOLINE RECEPTOR CONJUGATES - Disclosed are methods, compositions, and diagnostic kits for detecting acetylcholine receptor (AchR) autoreactive immune cells in a subject. The methods comprise detecting the binding of AChR-conjugate to penpheral blood AChR-specific B cells for diagnosing autoimmune disorders, including Myasthenia gravis (MG), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA). More specifically, the detection is achieved by using flow cytometric assay with Alexa-conjugated AchR. | 09-29-2011 |
20110269852 | METHODS AND MECHANISMS INVOLVING HYPERPIGMENTATION PARTICULARLY FOR AFRICAN AMERICAN SKIN - Sets of genes are identified that show modulated activity in hyperpigmented sun-exposed (HE) and non-hyperpigmented sun-exposed (NHE) skin, when compared to non-hyperpigmented non-exposed (NHNE) skin. The modulated sets of genes reveal important information about the genetic changes that take place in skin as a result of environmental exposure and damage. The modulated sets of genes may be used to fabricate custom DNA microarrays for evaluating patients with skin diseases or disorders. The microarrays may also be used to screen new substances for treating skin diseases and disorders. The modulated gene sets, and substances that target them, may also be used to develop therapies for individuals who suffer from hypopigmentation, such as those with Fitzpatrick type I skin or vitiligo. | 11-03-2011 |
20110313058 | METHOD AND APPARATUS FOR LIMITING GROWTH OF EYE LENGTH - Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders. | 12-22-2011 |
20120035279 | PROTOCOL FOR SCREENING TRAVELERS - Methods for screening a traveler for an evaluation of the traveler's physical condition or health status by obtaining at least one specimen from the traveler and subjecting the specimen to at least one test that is diagnostic for at least one parameter of the physical condition or health status of the traveler prior to or while the traveler undertakes a journey. Thereafter, the results of the diagnostic test are reported prior to or contemporaneous with the arrival of the traveler at the traveler's destination. | 02-09-2012 |
20120041082 | METHODS OF USING SMAD3 AND JAK2 GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2 loci. | 02-16-2012 |
20120065277 | MICROFLUIDIC CHEMOSTAT - A chemostat is described that includes a growth chamber having a plurality of compartments. Each of the compartments may be fluidly isolated from the rest of the growth chamber by one or more actuatable valves. The chemostat may also include a nutrient supply-line to supply growth medium to the growth chamber, and an output port to remove fluids from the growth chamber. Also, a method of preventing biofilm formation in a growth chamber of a chemostat is described. The method may include the steps of adding a lysis agent to a isolated portion of the growth chamber, and reuniting the isolated portion with the rest of the growth chamber. | 03-15-2012 |
20120095116 | PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION - A probe set comprising a detection probe and a counter probe, wherein the detection probe comprises an oligonucleotide which comprises a nucleotide sequence containing the mutation site on the target nucleic acid and also containing a nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence, has a fluorescent substance added to the 5′-terminal and a quenching substance added to the 3′-terminal, and has, introduced therein, such a modification that the melting temperature of the probe becomes 3° C. or more higher than that of the counter probe, and wherein the counter probe comprises an oligonucleotide which comprises a nucleotide sequence containing a mutation site and also containing a nucleotide that is different from the nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence. | 04-19-2012 |
20120095117 | GALECTIN-3 nsSNP MARKER FOR CANCER - A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H | 04-19-2012 |
20120129957 | ANALYZING THE FMR1 GENE - A method of screening a human for risk of malignancies is disclosed. The method may include isolating the human's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, measuring the number of triple CGG repeats on each of the first and second alleles, wherein the measuring step is conducted through use of an assay, and identifying the human as at risk for cancer when the triple CGG repeat number for at least one of the first and second alleles is less than 26. | 05-24-2012 |
20120149785 | METHOD OF ESTIMATING SEPSIS RISK IN AN INDIVIDUAL WITH INFECTION - A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome. | 06-14-2012 |
20120208899 | Tool for Assessment of Symptoms of Irritable Bowel Syndrome - Methods of treating and/or diagnosing irritable bowel syndrome (IBS) are provided, wherein treatment or diagnosis is undertaken on the basis of the patient's recordation of events associated with IBS in an event log and/or symptom diary. | 08-16-2012 |
20120208900 | METHODS OF PREDICTING THE NEED FOR SURGERY IN CROHN'S DISEASE - The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment. | 08-16-2012 |
20120214880 | CANCER SCREENING BY DETECTION OF ULTRASTRUCTURAL AND MOLECULAR MARKERS - The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject. | 08-23-2012 |
20120220671 | USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME - The present invention relates to materials and methods for predicting the risk of heart failure in a subject with Acute Coronary Syndrome. The invention further relates to monitoring the efficacy of treatment for heart failure in a subject with Acute Coronary Syndrome. | 08-30-2012 |
20120220672 | Presence of ERG Gene Rearrangements and Protein Over-expression in Low Grade PIN (LG-PIN) in Prostate Biopsies - The present disclosure relates to methods for the early detection of ERG over-expression, gene rearrangements, and diagnosis and/or prognosis of prostate cancer using a combined ERG IHC-FISH assay. | 08-30-2012 |
20120225954 | METHODS AND COMPOSITIONS FOR THE CLASSIFICATION OF NON-SMALL CELL LUNG CARCINOMA - The disclosure includes a method of screening for, diagnosing or detecting non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma in a subject. The method comprises:
| 09-06-2012 |
20120225955 | DETECTION OF AUTOANTIBODIES REACTIVE WITH PANCREATIC ISLET CELL ANTIGENIC MOLECULES AND/OR INSULIN - A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogues, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising `antigenic molecule of fist source!-`analyte auto antibody!-`antigenic molecule of second source! The antigenic molecule of first source is immobilised to a solid phase, the second is labeled. | 09-06-2012 |
20120232170 | Cleaning composition having high self-adhesion and providing residual benefits - A composition for treating a hard surface. The composition has: (a) at least one adhesion promoter; (b) at least one surfactant selected from the group consisting of: anionic, non-ionic, cationic, amphoteric, zwitterionic, and combinations thereof; (c) mineral oil; (d) water; (e) optionally, at least one solvent; and wherein the composition is self-adhering upon application to a surface to be treated, and wherein the composition provides a wet film to said surface when water passes over said composition and surface. | 09-13-2012 |
20120245235 | CLASSIFICATION OF CANCERS - A system for classifying a patient's cancer as belonging to one or more Cancer Modules of 1 of 15 different cancer types is provided. The Cancer Modules are useful to identify patient populations and individual patients demonstrating specific prognosis, risk of metastasis and/or recurrence, response or lack of response to drugs, and the like. | 09-27-2012 |
20120252907 | DIAGNOSTIC METHODS AND KIT FOR DETECTING CANCER - The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual. | 10-04-2012 |
20120259024 | POD FOR PROCESSING USED COOKING OILS AND PROCESSING APPARATUS - A pod for processing used cooking oils is disclosed that allows a higher energy efficiency of the process and better quality of the final result obtained, in view of different possible uses. This increase in terms of energy efficiency makes it possible to use an apparatus of the domestic appliance type, for processing a given quantity of used cooking oils together with the processing pod according to the invention. Providing the user with the possibility of opting among different combinations of functional substances provided in a main structure and in a secondary structure of the processing pod should, together with the possibility of using an apparatus of domestic use, allow the valorization of used cooking oils directly at the point of consumption. | 10-11-2012 |
20120270956 | USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER - The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type. | 10-25-2012 |
20120277326 | BIOMARKERS OF CANCER - Methods for diagnosis and staging of ovarian cancer, based on relative immunoreactivity of different IgG subclasses of autoantibodies, autoantibodies to defined antigens, e.g., antigens with specific subcellular localization, are described. | 11-01-2012 |
20120295990 | Insulin Receptor Substrate 1 (IRS1) Protein SRM/MRM Assay - The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IRS1 protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of IRS1 peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 11-22-2012 |
20120302649 | METHOD FOR SCREENING AMELIORANTS OF DRY SKIN CAUSED BY ATOPIC DERMATITIS USING BLEOMYCIN HYDROLASE ACTIVITY AS INDICATOR - The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug. | 11-29-2012 |
20120302650 | Insulin-Like Growth Factor 1 Receptor (IGF1R) Protein SRM/MRM Assay - The current disclosure provides for specific peptides from the Insulin-Like Growth Factor 1 Receptor (IGF-1R) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the IGF-1R directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IGF-1R protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an IGF-1R peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 11-29-2012 |
20120329886 | USE OF PERIOSTIN AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 12-27-2012 |
20130005836 | COMPOSITION AND METHODS RELATED TO S100 A2 - Compositions and methods related to diagnosis of ear infections and acute otitis media. | 01-03-2013 |
20130005837 | CANCER BIOMARKERS TO PREDICT RECURRENCE AND METASTATIC POTENTIAL - Described herein are methods for predicting recurrence, progression, and metastatic potential of a prostate cancer in a subject. In certain embodiments, the methods comprise analyzing a sample from a subject for aberrant expression patters of one or more biomarkers disclosed herein. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer. | 01-03-2013 |
20130012602 | METHODS OF USING ZNF365 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the ZNF365 genetic locus | 01-10-2013 |
20130012603 | METHODS FOR ASSESSING THE RISK OF CARDIOVASCULAR DISEASE - The studies described herein demonstrate that γ′ fibrinogen and total fibrinogen are independent risk factors for cardiovascular disease. Further described herein is the unexpected finding that an elevated concentration of γ′ fibrinogen in combination with an elevated concentration of total fibrinogen is a significantly better predictor of cardiovascular disease risk than either marker alone. Thus, provided herein are methods of detecting a subject having cardiovascular disease, or at increased risk of developing a cardiovascular disease, by measuring both the concentration of γ′ fibrinogen and the concentration of total fibrinogen in a sample obtained from the subject. | 01-10-2013 |
20130012604 | METHODS OF USING PRDM1 GENETIC VARIANTS TO PROGNOSE, DIAGNOSE AND TREAT INFLAMMATORY BOWEL DISEASE - Methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis are disclosed. | 01-10-2013 |
20130035404 | Integrated Analyses of Breast and Colorectal Cancers - Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy. | 02-07-2013 |
20130059930 | DIAGNOSTIC METHOD - The invention provides a method of detecting a subject suffering from, or at risk of suffering from, bladder cancer the method comprising
| 03-07-2013 |
20130059931 | ACTIVATION INDUCED DEAMINASE (AID) - The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide. | 03-07-2013 |
20130065972 | METHODS FOR SCREENING Th2 INFLAMMATORY DISEASES - The present invention provides a method for screening for a Th2 inflammatory disease in a subject comprising the steps of: assaying a miR-21 expression level in a biological sample from the subject, and comparing the miR-21 expression level in the biological sample from the subject to the miR-21 expression level in a control, wherein an increase in the miR-21 expression level in the biological sample from the subject compared to the miR-21 expression level in the control indicates the presence of Th2 inflammatory disease in the subject. | 03-14-2013 |
20130072581 | Secreted Protein Acidic and Rich in Cysteine (SPARC) Protein SRM Assay - The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 03-21-2013 |
20130072582 | METHODS FOR DIAGNOSING AND TREATING ENCEPHALITIS OR EPILEPSY - The invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to LGI1. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to LGI1 and treating a tumor associated with the disease. | 03-21-2013 |
20130079423 | DIAGNOSTIC METHODS INVOLVING LOSS OF HETEROZYGOSITY - The invention relates generally to methods of molecular analysis and particularly to methods of using genetic copy number variations and loss of heterozygosity in the characterization and treatment of disease. | 03-28-2013 |
20130079424 | METHODS FOR IDENTIFYING LEUKEMIA STEM CELLS AND DISTINGUISHING THEM FROM NORMAL HEMATOPIETIC STEM CELLS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: USES IN DIAGNOSIS, TREATMENT, AND RESEARCH - Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34 | 03-28-2013 |
20130079425 | Urokinase-Type Plasminogen Activator Protein /Plasminogen Activator Inhibitor Type-1 Protein Selected Reaction Monitoring Assay - Specific peptides are provided that are derived from subsequences of the urokinase-type plasminogen activator protein and the plasminogen activator inhibitor type-1 protein along with assays that can measure those peptides directly in complex protein lysate samples, including protein lysates prepared from histologicaly-processed formalin fixed tissue. The presence and amount of those peptides in samples from a subject can be associated with disease, including cancer, in a subject and provide information about the diagnostic stage/grade/status of the disease/cancer. | 03-28-2013 |
20130096212 | Method and a Kit to Predict Response to Antidepressant Treatment - The present invention relates to the method for predicting the pharmacoresponse of antidepressants in patients diagnosed with major depression and panic disorder. According to the invention, SNP (rs41271330) in the coding region of the BMP5 gene together with the markers in linkage disequilibrium with this SNP could be used as predictors of SSRI treatment efficacy. The knowledge obtained by using the method disclosed in present invention has potential to increase the efficacy of pharmacological treatment in patients with major depression and panic disorder. The invention also provides a kit for detecting individual who are likely to respond to antidepressant treatment. | 04-18-2013 |
20130102692 | METHODS FOR ASSESSING RISK OF ALZHEIMER'S DISEASE IN A PATIENT - Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis. | 04-25-2013 |
20130116343 | Salivary Protein Markers for Detection of Breast Cancer - A method of diagnosing a patient's risk of breast cancer comprises measuring in a saliva sample from the patient a concentration of at least a first protein marker, wherein the first protein marker is either ubiquitin or cytochrome p450, to provide a set of test data comprising a concentration value of each protein marker in the saliva sample. The test values are then compared to a reference panel comprising a Reference Control Value and a Reference Breast Cancer Value, and a diagnosis of either increased or decreased risk of breast cancer is determined for the patient based on a result of that comparison. A test kit for identifying a person at increased risk of breast cancer is also provided. | 05-09-2013 |
20130116344 | NUCLEIC ACIDS AND METHODS FOR DETECTING TURFGRASS PATHOGENIC FUNGI - The present invention relates to the use of at least one nucleic acid comprising or consisting of: | 05-09-2013 |
20130131194 | USE OF MICROVESICLES IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject. | 05-23-2013 |
20130131195 | c-Src Selected Reaction Monitoring Assay - Objective quantitation of the c-Src protein directly in cancer patient tissue can aid in determining the aggressiveness of an individual patient's tumor as well as help make more informed decisions about choice of therapy. However, the c-Src protein is currently analyzed directly in formalin fixed patient tissue only by immunohistochemistry methodology which is at best subjectively semi-quantitative. This invention describes an objective quantitative assay for the c-Src protein using mass spectrometry as the analytical methodology. Specific peptides, experimentally discovered characteristics about the peptides, and experimentally established assay conditions based on those peptide characteristics are provided for use in a mass spectrometry-based Selected Reaction Monitoring (SRM) assay in order to measure relative or absolute quantitative levels of c-Src directly in a protein preparation obtained from a formalin fixed cancer patient tissue sample. | 05-23-2013 |
20130150465 | PIG MODEL FOR BREAST CANCER, MITOCHONDRIA RELATED PROTEIN FOLDING DISORDERS AND/OR EPIDERMOLYSIS BULLOSA SIMPLEX - The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed. | 06-13-2013 |
20130172430 | PROGNOSIS AND TREATMENT OF BREAST CANCER - Methods of prognosis and monitoring of breast cancer include determining the level of one or more of the markers comprising asymmetric dimethyl arginine (ADMA), beta-hydroxybutyrate (BHB) and microRNA-31 (miR-31) in patient samples. An increased level is correlated with poor prognosis. Breast cancer is treated by administration of one or more inhibitors of ADMA and/or BHB. | 07-04-2013 |
20130172431 | DIAGNOSTIC TEST - Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention. | 07-04-2013 |
20130178543 | BIOMARKER FOR DIAGNOSING CANCER AND METHOD OF ISOLATING CANCER CELL USING THE SAME - A method of detecting a cancer stem cell or circulating tumor cell that has undergone epithelial-mesenchymal transition, comprising determining the level of caveolin-1 expressed by a sample cell, and comparing the level of caveolin-1 expressed by the sample cell to a control, wherein higher expression of caveolin-1 by the sample cell indicates that the sample cell is a cancer cell, as well as a method of detecting cancer or metastasis in a subject, and related methods and compositions. | 07-11-2013 |
20130178544 | METHOD FOR DIAGNOSIS AND MONITORING OF VIRAL INFECTION BY ANALYSIS OF VIRAL TRANSRENAL NUCLEIC ACIDS IN URINE - The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses. | 07-11-2013 |
20130197106 | METHODS OF IDENTIFYING A CANDIDATE COMPOUND - The invention relates to methods identifying compounds for the treatment of cell proliferation-related disorders, e.g., proliferative disorders such as cancer. | 08-01-2013 |
20130203870 | Animal Models of Atherosclerosis - The present invention provides transgenic, large non-human animal models of atherosclerosis and hypercholesterolemia, as well as methods of using such animal models in the identification and characterization of therapies for atherosclerosis and hypercholesterolemia. | 08-08-2013 |
20130203871 | FUIDI HERD MANAGEMENT SCHEMA - The invention is a herd management schema based upon the inventor's analysis of the natural history of bovine infection due to | 08-08-2013 |
20130231404 | GENOME-PHENOME ANALYZER AND METHODS OF USING SAME - The present invention features methods, devices, and systems, e.g., for providing diagnostic or treatment decision support to a clinician for the diagnosis or treatment of a patient in need thereof or for diagnosing or treating a patient in need thereof. | 09-05-2013 |
20130245135 | METHODS AND COMPOSITIONS FOR ASSESSING PATIENTS WITH PREECLAMPSIA-RELATED CONDITIONS USING MICRORNA - The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response. | 09-19-2013 |
20130261196 | Nucleic Acids For Multiplex Organism Detection and Methods Of Use And Making The Same - The invention provides mixtures of linear nucleic acid probes, including circularizing “capture” probes, capable of massively multiplex capture of one or more sequences of interest from a plurality of target organisms. The methods provided by the invention enable rapid, precise, and economical detection of one or more organisms of interest, such as common pathogens. | 10-03-2013 |
20130267613 | MOLECULAR-DETERMINANT BASED TYPING OF KIR ALLELES AND KIR-LIGANDS - The present invention relates to an assay to perform a molecular determinant-based functional killer immunoglobulin-like receptors (KIR) allele typing and ligand typing. In particular the present invention provides methods, compositions, and kits for a single nucleotide polymorphism (SNP) assay to type various allele groups of KIR2DL1 and KIR ligand with distinct functional properties based on polymorphism at position 245 in KIR2DL1, position 77 in HLA-C, and position 83 in HLA-B and HLA-A. The assays are suitable for use in predicting NK cell activity in health, disease, and transplantation. | 10-10-2013 |
20130289139 | DIAGNOSTIC ASSAY - The present disclosure relates generally to the field of immunological-based diagnostic assays. Particularly, a method is contemplated herein for measuring cell-mediated immune response reactivity. The present disclosure further provides a method to reduce incidence of non-specific immune response reactivity in a cell-mediated immune response-based assay, comprising contacting a sample with a basic peptide structure capable of binding to lipopolysaccharides, such as polymyxin B or a sushi peptide. | 10-31-2013 |
20130289140 | BIOLOGICAL COMPLEX SPECIFIC FOR ALZHEIMER'S DISEASE DETECTION IN VITRO AND USE THEREOF - A biomarker for Alzheimer's disease (AD) comprising a complex of an Aβ amyloid peptide and a cell or a cellular membrane. Non-invasive methods for diagnosing Alzheimer's disease or monitoring its development or progression using this biomarker. | 10-31-2013 |
20130289141 | Assessing Cardiac Disease Via Detection and Measurement of MicroRNA - Disclosed are methods and materials for assessing cardiac disease, including cardiac failure, cardiac hypertrophy, thoracic aortic aneurysm, left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum, or in cardiac tissue. | 10-31-2013 |
20130289142 | HER3 PROTEIN SRM/MRM ASSAY - The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3, that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the Her3 protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a Her3 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 10-31-2013 |
20130296447 | Method of Preventing Neurodevelopmental Damage Due to Prenatal Exposure to Environmental Toxins - A method of assessing the risk in female patients of having neurocognitive developmentally disabled children. The method including measuring the toxin concentrations in the urine of a female subject wishing to become pregnant, or of a subject that is pregnant. Quantify the risk of neurocognitive developmentally disabled children born to the subject by comparing the toxin concentrations in the subject to reference concentrations utilizing a weighting algorithm. Advise the patient of the quantified risk of having neurocognitive developmentally disabled children. The concentrations of dialkyl phosphates, endocrine disruptors, and xenoestrogens compounds are evaluated. Additionally, the level of PON1 activity may be included in the risk assessment weighting algorithm. | 11-07-2013 |
20130317123 | LARGE DELETIONS IN HUMAN PMS2 GENE AND USE THEREOF - Large deletions have been identified in the PMS2 gene in patients. The large deletions predispose the patients to Lynch syndrome associated cancers. | 11-28-2013 |
20130317124 | NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described. | 11-28-2013 |
20130317125 | NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described. | 11-28-2013 |
20130338242 | CLOUD MIXER AND METHOD OF MINIMIZING AGGLOMERATION OF PARTICULATES - An apparatus and a method for dispersing particulate materials prone to agglomeration, in a liquid. Particulate materials are exposed to a liquid and put into that liquid to form a suspension or a dispersion in a controlled method thereby minimizing agglomerates. The method uses mechanical/hydro mixing that prevents the physical deterioration of the particulate material and inhibits agglomeration of the particles. In many cases, these materials may be nanomaterials. Almost all particulate materials can be handled in this manner. This method has been found to be especially useful for preparing solutions of exfoliated graphene and certain drugs. | 12-19-2013 |
20130338243 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 12-19-2013 |
20130345322 | DIAGNOSTIC FOR COLORECTAL CANCER - The present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising determining the presence and/or level of biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer. | 12-26-2013 |
20140005281 | Method of Predicting Increased Risk of Suffering Statin-induced Adverse Drug Reactions | 01-02-2014 |
20140005282 | CMET PROTEIN SRM/MRM ASSAY | 01-02-2014 |
20140011895 | BIOMARKERS FOR SYSTEMIC LUPUS ERYTHEMATOSUS - The disclosure provides novel SLE biomarkers. The disclosure further provides kits and methods of diagnosing, prognosing, and stratifying subjects with the disease by utilizing the novel SLE biomarkers. | 01-09-2014 |
20140018445 | METHOD FOR DETECTION OF PATHOGENIC ORGANISMS - A method for detection of pathogenic organisms wherein the method includes differentiation between species. The method is especially suitable to detect and to diagnose infection by pathogenic organisms which are hard and/or laborious to detect with conventional methods. The method relies upon analysis of specific variable regions of the RNase P RNA gene, namely the P3 and/or P19 region(s). | 01-16-2014 |
20140018446 | Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease - Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor and identifying a subject as having dementia if the levels of the biomarkers is increased. | 01-16-2014 |
20140018447 | METHODS OF DIAGNOSING AND TREATING INTESTINAL GRANULOMAS AND LOW BONE DENSITY IN INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD). | 01-16-2014 |
20140018448 | ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE - The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis. | 01-16-2014 |
20140024725 | MODULATORS FOR TRPA1 FOR THE TREATMENT OF ROSACEA - An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRP) cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology. | 01-23-2014 |
20140051773 | METHODS FOR PREDICTING RISK OF DEVELOPING HYPERTENSION - Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension. | 02-20-2014 |
20140051774 | METHOD AND DEVICE FOR PRODUCING COMPOSITION HAVING DISPERSED PHASE FINELY DISPERSED IN CONTINUOUS PHASE - An object of the present invention is to provide a method for producing a composition having a disperse phase finely dispersed in a continuous phase with low polydispersity, the method which is excellent in production efficiency | 02-20-2014 |
20140058000 | DIAGNOSTIC MARKERS FOR DETERMINING THE PREDISPOSITION TO THE DEVELOPMENT OF CERVICAL CANCER AND OLIGONUCLEOTIDES USED FOR THE DETERMINATION - The present invention relates to a method for predisposition prediction of a subject to the development of cervical cancer and/or cancer precursors in an infection with the human papilloma virus (HPV) and/or for the detection of a persistent HPV infection, the method comprising the steps of obtaining a sample from the subject; and detecting at least one of the diagnostic markers or fragments thereof listed in Table 1 in the sample obtained from the subject. | 02-27-2014 |
20140088203 | METHOD FOR PREDICTING ABDOMINAL OBESITY - The present invention relates to a method, in particular an in vitro method, for predicting a risk of onset of abdominal obesity in a subject, which method comprises the steps of: a1) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) based on the result of the measurement in step a1), determining a risk of onset of abdominal obesity in the subject. | 03-27-2014 |
20140113978 | MULTIFOCAL HEPATOCELLULAR CARCINOMA MICRORNA EXPRESSION PATTERNS AND USES THEREOF - The present invention is directed to methods and products for defining a biomarker of disease phenotype. The present invention further relates to methods and kits for determining a subject's risk of developing recurrent hepatocellular carcinoma based on a defined microRNA biomarker that reliably distinguishes hepatocellular carcinoma disease recurrence from non-recurrence. The invention also relates to methods of treating a patient having heptocellular carcinoma based on their risk of developing hepatocellular carcinoma disease recurrence. | 04-24-2014 |
20140113979 | Compositions and Methods for Detecting Cancer - The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer. | 04-24-2014 |
20140121287 | MOLECULAR GRAM STAIN - The present invention relates to peptide nucleic acid (PNA) probes, PNA probe sets and methods for the analysis of Gram positive and Gram negative organisms optionally present in a sample. The invention further relates to diagnostic kits comprising such PNA probes. | 05-01-2014 |
20140155499 | BIOMARKERS OF OSTEOARTHRITIS - Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, Apolipoprotein A1, and Apolipoprotein E. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described. | 06-05-2014 |
20140163118 | Expression Signatures of Genes and Gene Networks Associated with Skin Aging - Described herein are expression signatures of genes and coordinately expressed gene networks associated with skin aging, methods used to determine the physiological age of skin, and methods used to screen for compounds used to reduce the visible signs of aging of the skin. | 06-12-2014 |
20140163119 | NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described. | 06-12-2014 |
20140171522 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries. | 06-19-2014 |
20140179805 | METHODS OF DETECTING DISEASES OR CONDITIONS - This invention provides methods of using a sample with multiple analytical components in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of identifying markers of diseases or conditions. | 06-26-2014 |
20140179806 | BIOMARKERS FOR EARLY DETERMINATION OF A CRITICAL OR LIFE THREATENING RESPONSE TO ILLNESS AND/OR TREATMENT RESPONSE - The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness. | 06-26-2014 |
20140179807 | MODULE-LEVEL ANALYSIS OF PERIPHERAL BLOOD LEUKOCYTE TRANSCRIPTIONAL PROFILES - The present invention includes an apparatus, system and method for the development and use of transcriptional modules by obtaining individual gene expression levels from cells obtained from one or more patients with a disease or condition; recording the expression value for each gene in a table that is divided into clusters; iteratively selecting gene expression values for one or more transcriptional modules by: selecting for the module the genes from each cluster that match in every disease or condition; removing the selected genes from the analysis; and repeating the process of gene expression value selection for genes that cluster in a sub-fraction of the diseases or conditions; and iteratively repeating the generation of modules. | 06-26-2014 |
20140179808 | Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens - Assays and reagents for the detection of autoantibodies to detect ovarian carcinomas are provided. | 06-26-2014 |
20140179809 | Determination Of Location Of Bacterial Load In The Lungs - The present invention is direct to methods of determining the location of a bacterial load in the lungs of a subject. | 06-26-2014 |
20140187652 | L-FABP BASED DIAGNOSIS OF KIDNEY INJURY AFTER AN ACUTE EVENT OR AFTER A SURGICAL INTERVENTION - Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future. | 07-03-2014 |
20140206775 | SRM/MRM Assay for the Fatty Acid Synthase Protein - Specific peptides, and derived ionization characteristics of the peptides, from the Fatty acid synthase (FASN) protein are provided that are particularly advantageous for quantifying the FASN protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the FASN protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of an FASN peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 07-24-2014 |
20140206776 | MRM/SRM Assay for Death Receptor 5 Protein - Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the DR5 protein are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the DR5 protein. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of a DR5 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence | 07-24-2014 |
20140206777 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE - The invention provides a method of diagnosing Alzheimer's disease (AD) in a subject by determining the level of expression of one or more miRNAs molecules associated with AD, as well as various nucleic acid molecules relating thereto or derived thereof. | 07-24-2014 |
20140213667 | METHOD OF PREVENTING AND TREATING AUTISTIC SPECTRUM DISORDER - A method of preventing and treating autistic spectrum disorder includes administration to a person of a product, which contains stable water clusters, such as stable double helix water clusters, by taking the products by mouth, applying the products on a skin of the person, intaking the product by breathing, introducing the products intravenously, etc. | 07-31-2014 |
20140221504 | Methods And Compositions For Detecting Aspergillus Terreus, Aspergillus Niger, And Mycotoxins - The invention relates to a method of identifying an | 08-07-2014 |
20140221505 | METHODS AND COMPOSITIONS FOR CATEGORIZING PATIENTS - The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data. | 08-07-2014 |
20140221506 | Methods of Diagnosing Neuropathic Pain - The invention includes compositions and methods useful for the diagnosis, assessment, and characterization of neuropathic pain in a subject in need thereof, based upon the expression level of at least one miRNA or snoRNA that is associated with neuropathic pain. | 08-07-2014 |
20140221507 | Biomarker of Renal Impairment - There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the reference value, c2) concluding that the subject belongs to the second group, wherein the sample is an optionally modified sample derived from urine or blood, such as an optionally diluted serum or plasma sample. Associated means are also provided. | 08-07-2014 |
20140235735 | Protein Damage in Aging and Age-Related Diseases - The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage. Methods of providing treatments that reduce intracellular reactive oxygen and/or nitrogen species, or protein-specific damage caused by reactive oxygen and/or nitrogen species, are disclosed. Furthermore, methods of screening for compounds that reduce intracellular reactive oxidative species, and/or molecules that prevent protein-specific damage by protecting the susceptible protein from such damage and therefore prevent or treat degenerative or age-related diseases, are also disclosed. | 08-21-2014 |
20140243431 | FLOURESCENT IN-SITU DETECTION OF LIPID PARTICLE APOLIPOPROTEINS WITHIN PRIMARY ELECTROPHORETIC MATRIX - The present invention relates to, among other things, a gel electrophoresis system for detecting the level of specific Apolipoproteins and/or lipoprotein particles present in intact lipid particles in a biological sample. The system includes a gel substrate to receive a biological sample, at least two lipoprotein-binding complexes. Each complex includes an antibody that binds a lipoprotein particle or a portion thereof, which is bound to a signal producing molecule capable of producing or causing production of a detectable signal. The system also includes a device for detecting the detectable signal. The present invention also relates to methods of assessing the level of specific Apolipoproteins and/or lipoprotein particles present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease, and monitoring the risk for developing cardiovascular disease. | 08-28-2014 |
20140243432 | PEPTIDE BIOMARKERS OF CARDIOVASCULAR DISEASE - The presently-disclosed subject matter provides methods for diagnosing a cardiovascular disease in a subject by determining an amount of one or more peptide biomarkers disclosed herein in a biological sample from the subject. The presently-disclosed subject matter further provides methods for determining treatment efficacy and/or progression of a cardiovascular disease in a subject by measuring amounts of one or more of the biomarkers in a biological sample from the subject. The presently-disclosed subject matter also provides antibodies and kits for measuring the biomarkers. | 08-28-2014 |
20140243433 | MARKER GENES FOR PROSTATE CANCER CLASSIFICATION - The present invention relates to a method for classifying a prostate cancer in a subject, the method comprising the steps of a) determining a gene expression level or gene expression pattern of the genes F3 and IGFBP3in a sample from the subject and b) classifying the tumor by comparing the gene expression level determined in a) with a reference gene expression of the same genes in reference patients known to have a high risk or low risk tumor respectively. In addition the invention relates to a method for determining prognosis of a subject diagnosed with prostate cancer, a method for making a treatment decision for a subject diagnosed with prostate cancer and a solid support or a kit for classifying a tumor in a subject diagnosed with prostate cancer. | 08-28-2014 |
20140249236 | Salivary mRNA Profiling, Biomarkers and Related Methods and Kits of Parts - A method to detect a biomarker in saliva wherein the biomarker is an extracellular mRNA, comprises detecting the extracellular mRNA in the cell-free saliva; transcriptome analysis of saliva comprises detecting a transcriptome pattern in the cell-free saliva; a method to detect genetic alterations in an organ or in a gene in the organ by analyzing saliva, comprises detecting a transcriptome pattern and/or the mRNA profiling of the gene in cell-free saliva; a method to diagnose an oral or systemic pathology disease or disorder in a subject, comprises: detecting profile of a biomarker associated with the pathology disease or disorder, in particular mRNA and/or protein, in cell-free saliva and/or serum; kits comprising identifier for at least one biomarker for performing at least one of the methods; and use of salivary biomarker salivary and/or serum mRNAs as biomarkers for oral and/or systemic pathology, disease or disorder. | 09-04-2014 |
20140275292 | SYSTEMS AND METHODS EMPLOYING HUMAN STEM CELL MARKERS FOR DETECTION, DIAGNOSIS AND TREATMENT OF CIRCULATING TUMOR CELLS - The invention relates to systems and methods to detect circulating tumor cells in a blood sample obtained from a cancer patient. Further, this invention relates to systems and methods to determine a diagnosis or prognosis of aggressive and metastatic cancer by determining the presence and/or level of circulating tumor cells in a blood sample obtained from a cancer patient. The detection and diagnosis is based on the presence or absence of cells that express podocalyxin and/or TRA biomarkers. | 09-18-2014 |
20140275293 | MEASUREMENT AND ANALYSIS OF MOLECULAR INTERACTIONS - The present invention relates to methods for measuring molecular interactions in a viscoelastic material, as well as related products and kits. The methods involve, for instance, taking multiple pressure measurements in the viscoelastic material and calculating the complex modulus from the pressure measurements to produce the measurement of viscoelastic properties in the viscoelastic material. Also included in the invention are methods and systems for detecting molecular interactions in vivo. | 09-18-2014 |
20140275294 | DEVICES AND METHODS FOR BIOMARKER DETECTION PROCESS AND ASSAY OF LIVER INJURY - An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of liver injury in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of liver injury in a biological sample, such as whole blood, plasma, serum. The inventive IVD device may measure one or more of several specific markers in a biological sample and output the results to a machine readable format wither to a display device or to a storage device internal or external to the IVD. | 09-18-2014 |
20140275295 | METHOD FOR TREATING TYPE I AND TYPE II DIABETES - The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of diabetes and diabetic conditions such as diabetic neuropathy, and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors. | 09-18-2014 |
20140296355 | UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER - A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer. | 10-02-2014 |
20140323593 | METHODS AND APPARATUS FOR THE CONTROL OF ADENOSINE TRIPHOSPHATE SYNTHASE ACTIVITY WITHIN LIVING ORGANISMS, AND CONDITIONING OF WATER-BASED FLUIDS AND SUBSTANCES USING MAGNETIC FIELD EXPOSURES OR THEIR WITHDRAWAL - The present invention relates to the control by magnetic fields (MF) of the activity of the mitochondrial enzyme adenosine triphosphate synthase (ATPS). Elimination of alternating and static MFs allows ATPS activity amplification (ATPSA), while a variety of MF frequency-intensity combinations interfere to various degrees with ATPS function (ATPSI). Control of ATPS, which is the endpoint of the mitochondrial oxidative phosphorylation system, allows alteration of intracellular adenosine triphosphate (ATP) levels, a molecule critical to the function of living organisms. Changes in ATP levels may trigger various events in cells, and prolonged ATPSI can lead to cell death. Specific combinations of MF frequencies and intensities maximize ATPSI for cancer cell killing and other health related applications. | 10-30-2014 |
20140323594 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries. | 10-30-2014 |
20140323595 | GM1 GANGLIOSIDE TO ANNEXIN V MICROPARTICLE POLYPEPTIDE RATIO FOR BIOLOGICAL MONITORING - We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of microparticles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism. | 10-30-2014 |
20140329917 | APPARATUS, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS - Apparatus, systems and methods are provided for the identification of various objects, particularly circulating tumor cells. In one aspect the system includes, but is not limited to, a scanning system, an image storage system, and an analysis system. The analysis system preferably identifies desired objects, such as complete cells, based on various criteria, which may include cell nuclear area or volume, CD-45 negative status, and cytokeratine positive status. Preferably included is a slide for containing the cells during the imaging step, the well including a planar bottom surface, a border at the periphery of the well defining sides for the well, the border being adjacent the bottom surface of the well and providing a fluidic seal there between. The invention herein provides for a single imaging well, providing for substantially a monolayer of objects, e.g., cells. | 11-06-2014 |
20140329918 | SPRAYHEAD FOR A SPRAY DEVICE - A sprayhead ( | 11-06-2014 |
20140336280 | COMPOSITIONS AND METHODS FOR DETECTING AND DETERMINING A PROGNOSIS FOR PROSTATE CANCER - The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection. | 11-13-2014 |
20140336281 | SRM/MRM Assay for the Ephrin Typa-A Receptor 2 Protein - Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the EPHA2 protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of an EPHA2 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 11-13-2014 |
20140336282 | MOLECULAR SIGNATURES OF INVASIVE CANCER SUBPOPULATIONS - Carcinomas typically invade as a cohesive multicellular unit, a process termed collective invasion. It remains unclear how different subpopulations of cancer cells contribute to this process. We developed three-dimensional (3D) organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer cells that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, K14+ cells led collective invasion in the major human breast cancer subtypes. Importantly, lumenal cancer cells were observed to convert phenotypically to invasive leaders following induction of basal epithelial genes. Although only a minority of cells within lumenal tumors expressed basal epithelial genes, knockdown of either K14 or p63 was sufficient to block collective invasion. Our data reveal that heterotypic interactions between epithelial subpopulations are critical to collective invasion. We suggest that targeting the basal invasive program could limit metastatic progression. | 11-13-2014 |
20140336283 | GENETIC FACTORS IN BLOOD PRESSURE - The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension. | 11-13-2014 |
20140343172 | COATING COMPOSITION - A barrier coating composition may include an alcohol-based binder and an inorganic particulate. The barrier coating composition may be used in various ways, including in paper products including the barrier composition, methods of preparing the paper products, articles, particularly food grade packaging formed from the paper products, and packaged products, particularly packaged foodstuffs including the packaging. | 11-20-2014 |
20140350129 | DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK - This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), and/or anti-CMV antibody. | 11-27-2014 |
20140350130 | MDM2-Containing Double Minute Chromosomes And Methods Therefore - Contemplated systems and methods allow for computational genomic analysis using paired-end sequence analysis and split read refinement to thereby identify high-confidence breakpoints associated with high copy numbers and orientation of rearrangements, which is then the basis for full reconstruction of double minutes (DM). In especially preferred aspects, the DM will also include an oncogene or tumor suppressor gene, and/or may be found in blood or blood derived fluids. | 11-27-2014 |
20140357732 | METHODS OF PREDICTING THE DEVELOPMENT OF COMPLEMENT-MEDIATED DISEASE - Described herein are methods for determining a Caucasian subject's susceptibility to having or developing a complement-mediated disease comprising determining in the Caucasian subject the identity of one or more haplotypes, wherein the presence of one or more of the haplotypes indicates the subject's susceptibility for having or developing a complement-mediated disease. | 12-04-2014 |
20140357733 | METHODS RELATING TO IDENTIFICATION OF SUSCEPTIBILITY TO LIVER INJURY - The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of PPAR-γ and TGFβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources. More specifically methods can be used to stratify liver disease patient populations to identify those most likely to progress to cirrhosis, or to identify the likelihood that a patient with liver disease will progress to having cirrhosis. | 12-04-2014 |
20140378558 | BIOMARKER FOR DETECTING CANCER - Methods for detecting colorectal cancer in a subject by detection of a galactose-containing 40 kDa molecule in a serum sample from the subject. Methods for quantifying the amount of a galactose-containing molecule in a serum sample are also provided. | 12-25-2014 |
20150031777 | miRNA FINGERPRINT IN THE DIAGNOSIS OF WILMS' TUMOUR - MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls. | 01-29-2015 |
20150038595 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Serum albumin, Protein S100-B, Glial cell line-derived neurotrophic factor, Resistin, Serum amyloid A protein, Hydrocortisone, Parathyroid hormone, and Tissue Plasminogen Activator as diagnostic and prognostic biomarkers in renal injuries. | 02-05-2015 |
20150038596 | Differential Diagnosis Of Cancer And Other Conditions Based On Expression Of p63 - This invention relates to methods of distinguishing among various types of differentiated and undifferentiated epithelial carcinomas, and non-epithelial carcinomas, by detecting the presence of p63 nucleic acid or protein expression. The invention also provides methods for detecting p63 nucleic acids and proteins, as well as methods for diagnosing and treating certain tumors based on whether the tumors express p63. | 02-05-2015 |
20150065587 | NUTRACUETICAL COMPOUNDING SYSTEM AND METHOD THEREFORE - The present invention relates to a system and process for a nutracuetical beverage compounding system and methods for the same. Provided is a customizable supplement beverage system and method for personalizing and operating the same to a particular user and optionally for operative tracking. Proposed additionally is an operative system for receiving and individually identifying a concentrate or supplement combinations, for mixing the same prior to a use, and for dispensing the same for use, and for tracking control factors relating to the same. | 03-05-2015 |
20150065588 | Tissue Culture Chip - A dual chamber bioreactor for producing complex, multilayer tissue, organs, organ parts, and skin replacements has been developed. The bioreactor is modular and incorporates a removable tissue culture cassette. By rotating the dual chamber bioreactor along the horizontal axis, different populations of cells with different growth requirements can be cultured on the different surfaces of the tissue culture cassette that are exposed to different media reservoirs. Culturing different populations of cells on different surfaces of the tissue culture cassette enables the production of multilayer tissue and organs. The tissue culture cassette can contain one or more discrete tissue culture sections. | 03-05-2015 |
20150080481 | Methods for renal neuromodulation - Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney. | 03-19-2015 |
20150087727 | METHOD FOR RISK STRATIFICATION IN STABLE CORONARY ARTERY DISEASE - An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations. | 03-26-2015 |
20150087728 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER - Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC). | 03-26-2015 |
20150094384 | METHODS FOR PREDICTING AND TREATING NECROTIZING ENTEROCOLITIS IN NEONATES - Embodiments are presented herein that provide early prediction of the development of necrotizing enterocolitis by a preterm infant through analysis of the high frequency component of heart rate variability, optionally with analysis of respiration rate. Methods of treatment following prediction area also reported. | 04-02-2015 |
20150099811 | METHOD AND SYSTEM TO DETECT AND DIAGNOSE ALZHEIMER'S DISEASE - Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the sample to identify at least one epigenetic marker and at least one of an inflammation marker and a cellular stress marker; determining an amount of the markers; performing a multivariate statistical analysis to produce an output value; comparing the output value to a reference value; and determining a state of Alzheimer's disease. | 04-09-2015 |
20150119475 | METHOD - The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity. | 04-30-2015 |
20150119476 | DEVELOPMENT, CHARACTERIZATION, AND USE OF AN ANTI-HYPUSINATED eIF5A ANTIBODY TO DIAGNOSE DIABETES - Provided herein is a comprehensive characterization of a novel polyclonal antibody (IU-88) that specifically recognizes the hypusinated eIF5A. The antibody IU-88 is useful for the investigation of eIF5A biology, for the development of assays recognizing hypusinated eIF5A, and for methods of treating conditions and diseases that involve the activity of hypusinated eIF5A. The antibody was used to determine that the levels of hypusinated eIF5A were elevated in the pancreatic tissues of patients diagnosed with Type 1 or Type 2 Diabetes. | 04-30-2015 |
20150126620 | METHODS FOR TREATING ANEMIA - The present invention relates to improved methods and compounds for treating anemia. Screening methods to identify agents for use in these treatment methods are also provided. | 05-07-2015 |
20150126621 | METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS - Described herein are miRNA-based methods for prognosis of recurrence of melanoma and related methods and kits. The present invention addresses these and other needs by providing a method for predicting the likelihood of recurrence of melanoma (including distal metastasis and locoregional recurrence) in a subject diagnosed with melanoma. In a separate aspect, the invention provides a method for treatment of a melanoma recurrence (including distal metastasis and locoregional recurrence) in a subject in need thereof. | 05-07-2015 |
20150126622 | Blood Biomarkers for Necrotizing Enterocolitis - Necrotizing Enterocolitis (NEC) biomarkers, NEC biomarker panels, and methods for obtaining a NEC signature for a sample are provided. Also provided are methods, compositions, and kits for making a Necrotizing Enterocolitis (NEC) assessment of an individual, e.g. for diagnosing NEC in a patient, prognosing NEC in a patient, treating an NEC patient, etc. These methods find use in a number of applications, such as diagnosing and treating infants who are suspected of having NEC, intestinal perforation (IP), or sepsis. | 05-07-2015 |
20150126623 | BIOMARKER OF DEPRESSION, METHOD FOR MEASURING BIOMARKER OF DEPRESSION, COMPUTER PROGRAM, AND RECORDING MEDIUM - A method for treating depression using a biomarker includes measuring a level of phosphoethanolamine in a blood sample collected from a subject, comparing the level of phosphoethanolamine in the blood sample with a predetermined threshold, in response to the level of phosphoethanolamine in the blood sample being below the predetermined threshold, determining that the subject requires a treatment for depression, and treating the subject determined to suffer from depression. | 05-07-2015 |
20150141528 | NEURAL SPECIFIC S100B FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION - An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD. | 05-21-2015 |
20150141529 | Method and Apparatus for Treating Centralized Pain - A method for alleviating centralized pain in human subjects includes assessing the brain of a subject suffering from pain, diagnosing abnormal brain function associated with centralized pain, locating at least one area of abnormal brain function associated with the centralized pain, and alleviating the abnormal brain function by applying a cortical stimulation signal to tissues corresponding to the at least one area of abnormal brain function. | 05-21-2015 |
20150141530 | METHOD AND SYSTEM FOR PREDICTING RECURRENCE AND NON-RECURRENCE OF MELANOMA USING SENTINEL LYMPH NODE BIOMARKERS - A method of characterizing melanoma in a subject involves determining the presence or level of one or more bio-markers in a sample obtained from a sentenal lymph node (SLN) of a subject. | 05-21-2015 |
20150148432 | ASSESSING SUSCEPTIBILITY TO VASCULAR DISORDERS - The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases. | 05-28-2015 |
20150290368 | Removal of Particulates from Blood Using an Apparatus Including a Size-Differentiating Element - The invention relates to methods of using an apparatus to sequester thrombi (including emboli) from blood of an animal such as a human. The apparatus comprises a stepped or sloped separation element interposed between an inlet region and an outlet region of a void that can be filled with fluid. The void can be enclosed within a cover and fluid flow through the void engages cells and thrombi/emboli in a blood sample with the separation element. Only particles (e.g., blood cells) which have or can deform to have a characteristic dimension smaller than or equal to the distance between a step and the cover or body can pass onto or past a step. By selecting dimensions which permit blood cells, but not thrombi or emboli, to pass onto or past a step and passing fluid through the apparatus, thrombi/emboli can be sequested from the blood sample. The thrombi can be observed, removed, or treated to effect their degradation or lysis. | 10-15-2015 |
20150292016 | NOVEL MARKERS FOR MENTAL DISORDERS - Methods and kits for diagnosing a psychiatric disorder such as schizophrenia, schizo-affective disorder, bipolar disorder or Tourette syndrome, or a predisposition thereto, in a subject, are disclosed. The methods and kits are based on the detection of the presence of SNP rs1156026, and/or of deletions located in introns of the DNAJC15 gene, in a biological sample from the subject. | 10-15-2015 |
20150292020 | miRNA Fingerprint in the Diagnosis of COPD - MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls. | 10-15-2015 |
20150292036 | CANCER SCREENING BY DETECTION OF ULTRASTRUCTURAL AND MOLECULAR MARKERS - The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject. | 10-15-2015 |
20150293121 | METHOD FOR TESTING FOR CARDIOVASCULAR DISEASE WITH CYCLOPHILIN A - An object of the present invention is to provide a novel examination method for a cardiovascular disease. As means for achieving the object, provided is an examination method for a cardiovascular disease, the method including the steps of: measuring a concentration of cyclophilin A protein in a human blood sample; and determining a probability of development of a cardiovascular disease based on the measured concentration of cyclophilin A protein. | 10-15-2015 |
20150299792 | ASSESSING RISK OF READING AND LANGUAGE IMPAIRMENT - Described herein are the association BV677278 (READ1) with reading disability and language impairment, as well as the synergistic interaction of DCDC2 risk haplotypes or alleles with KIAA0319 risk allele. | 10-22-2015 |
20150299808 | COMPOSITIONS AND METHODS FOR DIAGNOSING THYROID TUMORS - The present invention provides dignostic assays for identifying thyroid cancer in a biological sample, including a fine needle aspirate, as well as related compositions and kits useful in practicing the methods of the invention. | 10-22-2015 |
20150306030 | Method of Liquefying Solid Form of Medication - A method of liquefying solid form of medication into a liquefied medication solution is implemented by a medication liquefaction system and a removable medicine container. The solid form medication, which is difficult to swallow by itself, and a desired amount of drinkable fluid base product are added into the removable medicine container before the removable medicine container is hermetically attached with the medication liquefaction system. Then a carbon dioxide (CO | 10-29-2015 |
20150307948 | PROSTATE CANCER PROGNOSTIC COMPOSITIONS AND KITS - Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. | 10-29-2015 |
20150322520 | Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression - The present invention is related to novel methods for categorizing and treating a population of subjects that are at risk for increased pulmonary exacerbation and disease progression. | 11-12-2015 |
20150322533 | PROGNOSIS OF BREAST CANCER PATIENTS BY MONITORING THE EXPRESSION OF TWO GENES - The present invention relates to the expression of two genes, CyclinG | 11-12-2015 |
20150329910 | Methods of Detecting Diseases or Conditions Using Phagocytic Cells - This invention provides methods of using phagocytic cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using phagocytic cells to identify markers of diseases or conditions. | 11-19-2015 |
20150329914 | PREDICTIVE BIOMARKERS FOR PRE-MALIGNANT BREAST LESIONS - The invention is based on the discovery of biomarkers and gene signatures that are useful for determining the presence of atypical hyperplasia in a breast lesion, and for determining whether a pre-malignant breast lesion is likely to progress to breast cancer. In particular, the present invention provides methods and reagents for detecting and profiling the expression levels of these biomarkers and genes, and methods of using the expression profiles for predicting the likelihood that a pre-malignant lesion will progress to breast cancer. | 11-19-2015 |
20150329917 | Method for Monitoring Disease Progression or Recurrence - The invention provides methods for detecting and monitoring diseases associated with genetic abnormalities in a subject. | 11-19-2015 |
20150335740 | METHOD FOR PRODUCTION OF SOLID WATER PARTICLES FOR HOMEOPATHY - A method for production of solid water particles for homeopathy uses principles of quantum physics to from a concentrated solid water particle solution. A homeopathic ingredient solution is diluted in purified water in an inert gas environment. The dilution occurs as infinitesimal doses, in which the solution is repetitively diluted in water past the point where few molecules from the solution remain. An electrical field is applied to align the water molecules for formation of a large clump of solid water particles. Alternating phases of ultrasonic vibrations break down the large clump into small clusters of solid water particles. The vibration is followed by periods of rest, whereby the small clusters grow into successively larger clumps by absorbing water molecules. The vibrations and resting are repeated in cycles until a desired concentration of solid water particles form in the solid water particle solution. | 11-26-2015 |
20150344960 | Single Nucleotide Polymorphisms (SNPs) in Genes Accociated With Inflammatory Diseases - The present disclosure describes the identification of single nucleotide polymorphisms (SNPs) in inflammatory diseases and uses thereof, and methods of screening for, diagnosing, identifying susceptibility to or detecting a risk of developing an inflammatory disease comprising detecting the presence or absence of at least one SNP identified in a gene associated with inflammatory disease. | 12-03-2015 |
20150344977 | Method And System For Detection Of An Organism - Provided herein are systems and method of detecting an organism, such as a microbe, microorganism or pathogen. The system can comprise one or more probi for detecting a strain with high sensitivity. The system can also detect the strain within a short time frame. | 12-03-2015 |
20150353988 | Borrelia Provocation Procedure Kit - The testing for the Lyme disease pathogen, ( | 12-10-2015 |
20150355194 | MARKERS FOR LIPID METABOLISM - Disclosed herein is a method for treating obesity in a subject in need thereof. Also disclosed herein is a method for protecting a subject in need thereof from obesity. Further disclosed herein is a method for monitoring an efficacy of a treatment for obesity in a subject. | 12-10-2015 |
20150359889 | Cardiac arrest muscle relaxant - Muscle Relaxants for Cardiac Arrest Patients | 12-17-2015 |
20150368725 | DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN KRAS - Disclosed herein are primers and probes for the detection of single nucleotide polymorphisms (SNPs) in the KRAS gene. These primers and probes may be used in a method of identifying the presence or absence of one or more SNPs in the KRAS gene. These primers and probes may also be used in a method of predicting a response of a subject in need thereof to a cancer therapy. The primers and probes may further be used in a method of selecting a cancer therapy for a subject in need thereof. | 12-24-2015 |
20150369811 | METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER - The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis. | 12-24-2015 |
20150369818 | HER3 PROTEIN SRM/MRM ASSAY - The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3, that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the Her3 protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a Her3 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 12-24-2015 |
20150376678 | SRM Assay to Indicate Cancer Therapy - The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from the biological sample using the Liquid Tissue™ reagents and protocol and the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry, by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of an ALK, Ros, Ron, Ret, TS, and/or FGFR1 fragment peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 12-31-2015 |
20150376698 | METHOD FOR ESTABLISHING THE SOURCE OF INFECTION IN A CASE OF FEVER OF UNCLEAR AETIOLOGY - Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract. | 12-31-2015 |
20150376713 | BIOMARKERS AND METHODS FOR PREDICTING BENEFIT OF ADJUVANT CHEMOTHERAPY - Biomarkers, methods, assays, and kits are provided for predicting the efficacy of adjuvant chemotherapy (ACT) in a subject with early-stage non-small cell lung cancer (NSCLC). | 12-31-2015 |
20160003846 | METHOD FOR INHIBITING THE SWAP-70 PROTEIN - The invention relates to the field of biomedical and pharmacological research, in particular in the field of immunology, allergies, cancers, bone diseases and autoimmune diseases. | 01-07-2016 |
20160003850 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine-protein kinase erbB-2, Interferon beta, C-type lectin domain family 11 member A, Glyceraldehyde-3-phosphate dehydrogenase, Interferon omega-1, Coagulation factor VIII, Thrombin-Antithrombin-III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries. | 01-07-2016 |
20160010160 | PROGNOSTIC METHOD | 01-14-2016 |
20160011194 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | 01-14-2016 |
20160011208 | ASSAY FOR POLYPEPTIDE AGGREGATION USING MICRODROPLETS | 01-14-2016 |
20160046983 | Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor - The present invention provides a method of specifically detecting the presence of one or more Mycobacteria of the | 02-18-2016 |
20160047801 | METHOD AND SYSTEM TO DETECT, DIAGNOSE, AND MONITOR THE PROGRESSION OF ALZHEIMER'S DISEASE - Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease. | 02-18-2016 |
20160047811 | METHODS FOR ASSESSING THE RISK OF CARDIOVASCULAR DISEASE - The studies described herein demonstrate that γ′ fibrinogen and total fibrinogen are independent risk factors for cardiovascular disease. Further described herein is the unexpected finding that an elevated concentration of γ′ fibrinogen in combination with an elevated concentration of total fibrinogen is a significantly better predictor of cardiovascular disease risk than either marker alone. Thus, provided herein are methods of detecting a subject having cardiovascular disease, or at increased risk of developing a cardiovascular disease, by measuring both the concentration of γ′ fibrinogen and the concentration of total fibrinogen in a sample obtained from the subject. | 02-18-2016 |
20160053326 | TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS - The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREE3, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis. | 02-25-2016 |
20160054306 | The cause and possible treatment of thyroid anti-body disease - The discovery presents the means for confident diagnosis of chronic inflammatory disease of ovaries such as PID. The hormone producing function of ovaries is one of the main functions of them and if that function is disrupted, it could have the meaning that present is the condition of ovaries that requires treatment. | 02-25-2016 |
20160055295 | BIOMARKER IDENTIFICATION - Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS. | 02-25-2016 |
20160068912 | METHOD FOR DETERMINING RISK OF METASTATIC RELAPSE IN A PATIENT DIAGNOSED WITH COLORECTAL CANCER - The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene. | 03-10-2016 |
20160068913 | Methods for Lung Cancer Detection - The disclosure describes a method for diagnosing lung cancer in a subject by detecting in a biological sample obtained from that patient a miRNA signature, the presence of which provides an earlier indication of cancer than alternative art-recognized methods, including, but not limited to, low-dose computed tomography (LDCT). | 03-10-2016 |
20160069883 | BIOMARKERS FOR DETECTION OF BREAST CANCER - Methods are provided for predicting and diagnosing the presence of breast cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. | 03-10-2016 |
20160069884 | BIOMARKERS FOR DISTINGUISHING BETWEEN AGGRESSIVE PROSTATE CANCER AND NON-AGGRESSIVE PROSTATE CANCER - The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer. In one embodiment, a method for identifying patients as having or likely to have aggressive prostate cancer comprises the steps of (a) performing an assay on a biological sample obtained from the patient to detect fucosylated prostate specific antigen (PSA), transmembrane prostate androgen-induced protein, kallikrein-2, lipid phosphate phosphohydrolase 3, heparan-sulfate 6-O-sulfotransferase, prostatic acid phosphatase (PAP), nuclear RNA export factor 2, and protein POF1B; and (b) identifying the patient as having or likely to have aggressive prostate cancer if there is a statistically significant difference in the levels of fucosylated PSA, transmembrane prostate androgen-induced protein, kallikrein-2, lipid phosphate phosphohydrolase 3, heparan-sulfate 6-O-sulfotransferase, PAP, nuclear RNA export factor 2, and protein POF1B as compared to corresponding levels in a control sample that correlates to non-aggressive prostate cancer. | 03-10-2016 |
20160074510 | METHOD AND DEVICE TO DELIVER ANTIFIBRINOLYTIC DRUGS TO IMPEDE TUMOR GROWTH AND INCREASE THE RADIO SENSITIVITY OF CANCEROUS TISSUE - Antifibrinolytic agents/drugs are applied to a cancerous area to impede tissue growth and increase the radio sensitivity of cancerous tissue. Various techniques are described for administering the antifibrinolytic agent. | 03-17-2016 |
20160083795 | BIOMARKERS - The present invention relates to novel biomarkers for determining the Alzheimer's disease status of a subject, and to uses of novel panels of biomarkers. AD is currently clinically diagnosed using tests of cognitive function. Studies have shown that the accuracy of the clinical diagnosis is between 65 and 90% using cognitive techniques. The present invention provides a method of determining the Alzheimer' s disease status of a subject comprising providing a sample of material obtained from the subject and determining the expression level of one or more genes selected from the group consisting of: TUBB, NEAT1, CENPB, AA482221 and CPSF3 in the sample. | 03-24-2016 |
20160090629 | VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE - Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci. | 03-31-2016 |
20160097082 | PROSTATE SPECIFIC ANTIGEN PROTEOLYTIC ACTIVITY FOR CLINICAL USE - Methods for predicting the outcome of and monitoring prostate cancer patients using prostate specific antigen (PSA) proteolytic activity (PPA) in combination with other molecular biomarkers or other parameters are described. Methods of determining sets of parameters for use in predicting the outcome of and monitoring of prostate cancer patients are also described. | 04-07-2016 |
20160122806 | CUSTOMIZED SKIN CARE PRODUCTS AND PERSONAL CARE PRODUCTS BASED ON THE ANALYSIS OF SKIN FLORA - Present invention relate to a combination of experimental and computational workflows that allow characterization of skin and subcutaneous tissue microbial flora and its associated metabolome, aiming to first evaluate an individual's skin and subcutaneous tissue to determine if any skin condition is as a result of an imbalance or absence of commensal or mutualistic microorganisms or their associated metabolites. The methods and the associated computational platform provided herein relate to conducting a customized or personalized test and obtaining customized or personalized information regarding the skin and subcutaneous tissue flora and its associated metabolome there from also have been disclosed. | 05-05-2016 |
20160139151 | METHODS AND COMPOSITIONS RELATING TO NEURODEGENERATIVE DISEASES - The present invention provides a method for diagnosing or assessing a neurodegenerative disease in a test subject, comprising: (i) providing a protein-containing sample that has been obtained from the test subject; (ii) determining the concentration, amount or degree of expression of at least one specific protein isoform and/or glycoform derived from a protein biomarker selected from the group consisting of: clusterin precursor; apolipoprotein A-IV precursor; apolipoprotein C-III precursor; transthyretin; galectin 7; complement C4 precursor; alpha-2-macroglobulin precursor; Ig alpha-1 chain C; histone 2B; Ig lambda chain C region; fibrinogen gamma chain precursor; complement factor H; inter-alpha-trypsin heavy chain H4 precursor; complement C3 precursor; gamma or beta actin; haptoglobin precursor; and the serum albumin precursor, or a fragment thereof; (iii) comparing said concentration, amount or degree determined in (ii) with a reference from a control subject with a specific neurodegenerative disease, dementia or stage of disease, or from a control subject that does not have a neurogenerative disease or dementia; and (iv) based on the level of the at least one specific protein isoform and/or glycoform of the protein biomarker in the test subject relative to the reference, making a diagnosis or assessment as to the presence of and/or stage of neurodegenerative disease or dementia of the test subject. Also provided are related products and systems for use in such a method. | 05-19-2016 |
20160145690 | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions - This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions. | 05-26-2016 |
20160146834 | DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK - This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), urokinase or urokinase receptor (uPA/uPAR), and/or anti-CMV antibody. | 05-26-2016 |
20160150762 | PORTABLE SYSTEM FOR DISPENSING FLUIDS FOR ANIMALS | 06-02-2016 |
20160153967 | Methods of Detecting Cardiovascular Diseases or Conditions | 06-02-2016 |
20160153984 | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions | 06-02-2016 |
20160153993 | SIGNATURES AND DETERMINANTS FOR DISTINGUISHING BETWEEN A BACTERIAL AND VIRAL INFECTION AND METHODS OF USE THEREOF | 06-02-2016 |
20160160283 | Methods of Detecting Kidney-Associated Diseases or Conditions - This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of kidney-associated diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of kidney-associated diseases or conditions. | 06-09-2016 |
20160160284 | Methods of Detecting Neurological or Neuropsychiatric Diseases or Conditions - This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of neurological or neuropsychiatric diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of neurological or neuropsychiatric diseases or conditions. | 06-09-2016 |
20160175443 | Treatment options for allergies | 06-23-2016 |
20160175444 | Treatment for non-genetic biological disease | 06-23-2016 |
20160187343 | COMPOSITIONS AND METHODS FOR IDENTIFYING A RISK OF CANCER IN A SUBJECT - Disclosed herein are compositions and methods for determining a risk of cancer, such as head and neck squamous cell carcinoma, in a subject using a bodily fluid sample from the subject and assays for markers such as solCD44 and total protein. Also disclosed are methods of treating a subject based on said risk. Methods of determining the efficacy of a cancer treatment are also disclosed. | 06-30-2016 |
20160194717 | Methods of Detecting Diseases or Conditions Using Phagocytic Cells | 07-07-2016 |
20160195529 | METHODS AND KITS FOR DETERMINING TUBERCULOSIS INFECTION STATUS | 07-07-2016 |
20160251722 | BRCA2-SPECIFIC MODIFIER LOCUS RELATED TO BREAST CANCER RISK | 09-01-2016 |
20160252525 | CMET PROTEIN SRM/MRM ASSAY | 09-01-2016 |
20160252536 | FLUORESCENT IN-SITU DETECTION OF LIPID PARTICLE APOLIPOPROTEINS WITHIN PRIMARY ELECTROPHORETIC MATRIX | 09-01-2016 |
20160376652 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND PREDICTION OF SOLID ORGAN GRAFT REJECTION - Provided herein are methods, compositions, systems, and kits for diagnosing acute rejection of solid organ transplants using at least 5 genes selected from a 10-gene panel. | 12-29-2016 |
20160376657 | METHOD OF DIAGNOSING RENAL DISORDERS - The invention refers to an in vitro method of determining the risk of renal disorders, in a patient, by measuring a VCAN parameter, characterized in that at least one of the isoforms V0 and V1 are specifically determined in a sample of said patient and compared to a reference level. | 12-29-2016 |
20160377602 | IMMUNE MONITORING TO PREDICT AND PREVENT INFECTION - Methods of evaluating the risk of infection after transplantation or immunosuppression in a subject are provided. Methods of determining whether a subject should be treated prophylactically with an anti-microbial agent are also provided herein. Kits for performing the methods described herein are also provided. | 12-29-2016 |
20160377625 | ARMET AS A MARKER FOR CANCER - Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 12-29-2016 |
20170233793 | Borrellia Provocation Procedure Protocol | 08-17-2017 |
20170233822 | MicroRNA Biomarker for the Diagnosis of Gastric Cancer | 08-17-2017 |
20170234873 | SIGNATURES AND DETERMINANTS FOR DIAGNOSING INFECTIONS IN NON-HUMAN SUBJECTS AND METHODS OF USE THEREOF | 08-17-2017 |
20180024138 | FRIZZLED-4 MUTATION INDICATOR OF RETINOPATHY AND INTRAUTERINE GROWTH RESTRICTION | 01-25-2018 |
20190144944 | TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS | 05-16-2019 |
20220136061 | TREATMENT AND DETECTION OF MELANOMA - Provided are methods for determining or predicting the diagnosis, prognosis, treatment and therapeutic efficacy of melanoma in a subject, which include evaluating the expression level of one or more miRNA biomarkers including miRNA-4487, miRNA-4706, miRNA-4731 and fragments or variants thereof as an indication of whether the subject may have, or be predisposed to, melanoma. | 05-05-2022 |